<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370171</url>
  </required_header>
  <id_info>
    <org_study_id>7775</org_study_id>
    <nct_id>NCT04370171</nct_id>
  </id_info>
  <brief_title>Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic</brief_title>
  <acronym>TeleCoviDiab</acronym>
  <official_title>Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic: Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the end of February 2020, Covid-19 infection has spread widely in France, particularly&#xD;
      in the East region, with on March 25th, 2020, 5,479 infected patients and 407 deceased&#xD;
      patients, including 256 in Alsace. Among the hospitalized patients reported in the initial&#xD;
      Chinese studies, 48% had co-morbidity, particularly diabetes or cardiovascular disease.&#xD;
      Covid-19 infection does not appear to be more common in diabetic patients, but infected&#xD;
      diabetics have more severe forms.&#xD;
&#xD;
      The prevalence of diabetes is high in Alsace affecting 6.5% of the population against 4.6% in&#xD;
      France. Du to health containment measures, asymptomatic diabetic patients can no longer come&#xD;
      to the clinic in Hospital for their consultation. However, in the current epidemiological&#xD;
      context, maintaining optimal glycemic control is fundamental since some of diabetic patients&#xD;
      will have Covid-19 infections. Furthermore, the sedentary lifestyle and snacking linked to&#xD;
      the confinement period will contribute to a glycemic imbalance in some patients.&#xD;
      Telemedicine, and in particular teleconsultation, which until now has been very uncommon in&#xD;
      the management of diabetic patients, represents a very interesting alternative for monitoring&#xD;
      these patients and maintaining satisfactory metabolic control during the current period of&#xD;
      confinement and Covid-19 epidemic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Actual">May 29, 2020</completion_date>
  <primary_completion_date type="Actual">May 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of metabolic control (HbA1C) between diabetic patients followed by teleconsultation and patients with a conventional follow-up during Covid-19 infection.</measure>
    <time_frame>HbA1C measured at 3 months post-telemedicine consultation group / post-cancellation of the face-to-face consultation group (variation versus basal)</time_frame>
    <description>In the Covid 19 epidemic context, the face-to-face consultation of diabetic patients with the hospital's physician or their diabetologist is / will be replaced by a teleconsultation ( phone or computer consultation) followed at 6 months of a face-to-face consultation. Patients will be monitored in accordance with routine practice.&#xD;
The Teleconsultation (TC) group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.&#xD;
The Face-to-Face group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was postponed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1C measured at 6 months post-telemedicine consultation for the TC group / post-cancellation of the face-to-face consultation for the P group.</measure>
    <time_frame>HbA1C will be measured at visit V2 (6 months after inclusion visit)=through study completion, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of patients inaccessible to teleconsultation and number of patients inaccessible by type of associated reason.</measure>
    <time_frame>Total number of patients inaccessible to teleconsultation will be collected through study completion, an average of 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of complications: severe hypoglycemia, ketoacidosis, myocardial infarction, stroke, foot ulcer.</measure>
    <time_frame>Number of complications through study completion, an average of 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of patient satisfaction questionnaire.</measure>
    <time_frame>Patients will respond to the questionnaires either at the end of study (6 months after inclusion) or in the month following the teleconsultation.</time_frame>
    <description>This questionnaire is not a score on a scale, there is no minimum or maximum values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of doctor satisfaction questionnaire.</measure>
    <time_frame>Physician will respond to the questionnaires at study completion, 6 months after the inclusion visit.</time_frame>
    <description>This questionnaire is not a score on a scale, there is no minimum or maximum values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients infected with Covid-19 (positive smear by RT-PCR for SARS-CoV-2 virus).</measure>
    <time_frame>Number of patients infected with Covid-19 during the study (6 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of conventional hospitalizations, in intensive care and deaths.</measure>
    <time_frame>Number of conventional hospitalizations, in intensive care and deaths during the study (6 months).</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">610</enrollment>
  <condition>Diabetes</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Group TC: Diabetic patients followed by Teleconsultation</arm_group_label>
    <description>Teleconsultation group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist has been replaced by a teleconsultation due to the availability of diabetologists whose activity is focused on the management of Covid-19 negative patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P: Diabetic patients with conventional follow-up</arm_group_label>
    <description>Conventional group will be composed of patients for whom the consultation initially scheduled in the presence of the diabetologist was differed by 6 months due to the activity of some diabetologists entirely redirected towards the management of Covid-19 positive patients and not available</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>care modalities</intervention_name>
    <description>For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.</description>
    <arm_group_label>Group P: Diabetic patients with conventional follow-up</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Teleconsultation either by phone or by computer consultation</intervention_name>
    <description>Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation</description>
    <arm_group_label>Group TC: Diabetic patients followed by Teleconsultation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic patients regularly followed in a clinic at the University Hospital of Strasbourg&#xD;
        or followed by a liberal diabetologist in Strasbourg&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult diabetic patient (type 1,2, MODY, secondary, post transplantation) followed by&#xD;
             diabetology consultation at the hospital or by a liberal diabetologist&#xD;
&#xD;
          -  Subject affiliated to a social health insurance&#xD;
&#xD;
          -  Subject able to understand the objectives of the research&#xD;
&#xD;
          -  Subject who expressed his non opposition to the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Patients with acute complications (foot ulcer, post stroke, post IDM)&#xD;
&#xD;
          -  Cancer or life expectancy of less than 6 months&#xD;
&#xD;
          -  Inability to provide informed information to the subject (subject in an emergency,&#xD;
             difficulty of understanding for the subject, etc.)&#xD;
&#xD;
          -  Subject under judicial protection&#xD;
&#xD;
          -  Subject under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HÃ´pitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>Covid-19 epidemic</keyword>
  <keyword>Glucose control</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

